Soleus Capital Management, L.P. Castle Biosciences Inc Transaction History
Soleus Capital Management, L.P.
- $1.44 Billion
- Q4 2024
A detailed history of Soleus Capital Management, L.P. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 252,917 shares of CSTL stock, worth $5.62 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
252,917
Previous 662,332
61.81%
Holding current value
$5.62 Million
Previous $18.9 Million
64.32%
% of portfolio
0.47%
Previous 1.6%
Shares
10 transactions
Others Institutions Holding CSTL
# of Institutions
210Shares Held
26.6MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$67.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$40.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$39.9 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$31.9 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$22.2 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $585M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...